Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA complete response letter in August 2026.
Media partner
M&A · RADIOPHARMACEUTICAL M&A · SEPTEMBER 26, 2026 · GLOBAL
Vertical integration is now the defining strategic logic of the radiopharmaceutical sector. Telix Pharmaceuticals, a Melbourne-based biopharmaceutical company listed on the Australian Securities Exchange (ASX) and NASDAQ (ticker: TLX), announced on 21 September 2026 an agreement to acquire ITM Isotope Technologies Munich SE, a German radiopharmaceutical company specialising in medical isotope production, in a transaction worth up to $2.35 billion. The deal gives Telix direct ownership of a major isotope supplier — removing a critical external dependency — while simultaneously adding ITM-11 (no-carrier-added lutetium-177 edotreotide), a late-stage drug candidate for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), to its therapeutic pipeline.
The financial structure is layered. Telix will pay $1.65 billion upfront on a cash-free, debt-free basis, of which $1.25 billion will be settled in 105.8 million Telix shares priced at $11.841 apiece, the 30-day trailing volume-weighted average price as of signing, according to Telix. The upfront amount also includes $302 million of assumed ITM net debt. A further $700 million is contingent on specified regulatory approvals and sales milestones for ITM-11: up to $250 million tied to U.S. Food and Drug Administration (FDA) approval across three indications, and up to $450 million tied to ITM-11 global net sales in fiscal 2030 exceeding $150 million. After completion, ITM’s shareholders are expected to hold approximately 23.7% of Telix.
A Supply Chain Bet Wrapped Around a Pipeline Wager
The two components of the deal carry distinct risk profiles. The manufacturing and isotope-supply rationale is operationally straightforward: by September 2024 Telix had spent roughly $1 billion on acquisitions over the preceding two years, per Fierce Pharma, building out a radiopharmacy and production network that includes RLS Radiopharmacies — a network of 31 radiopharmacies across 18 U.S. states, acquired in a deal announced in 2024 for up to $250 million — and the earlier purchase of isotope producer ARTMS for $82 million. ITM’s manufacturing business extends that vertical stack upstream into isotope origination. The precise valuation allocation between manufacturing and pipeline has not been publicly disclosed.
The pipeline component is a separate wager. ITM-11 has completed a Phase 3 trial (COMPETE) and a second Phase 3 study (COMPOSE) is fully enrolled, with an interim analysis expected in the first half of 2027, according to Telix. On 10 August 2026, ITM disclosed that the FDA had issued a complete response letter (CRL) on the ITM-11 new drug application (NDA), citing chemistry, manufacturing and controls (CMC) and “third-party commercial facility-related items”; ITM said the FDA “did not identify any concerns regarding the clinical or nonclinical data package or safety profile of ITM-11,” and that it intends to resubmit.
Consolidation Pressure on Remaining Independent Operators
The Telix-ITM transaction arrives weeks after Curium, a privately held radiopharmaceutical company controlled by investment firm CapVest Partners, agreed on 3 August 2026 to acquire Lantheus Holdings for up to $8 billion, per Curium’s announcement. That deal would unite Curium’s global manufacturing network — more than 80 sites, a presence in more than 70 countries and over 3,800 employees — with Lantheus’s U.S. radiodiagnostics franchise, led by piflufolastat F-18 (Pylarify), a prostate cancer positron emission tomography (PET) imaging agent, alongside the cardiac ultrasound enhancing agent perflutren lipid microsphere (Definity) and the beta-amyloid PET imaging agent florbetaben (Neuraceq). Lantheus reported $377.3 million in worldwide revenue in the first quarter of 2026, and suspended its 2026 guidance following the deal announcement.
Together, the two transactions suggest the sector is moving toward a structure in which isotope production, manufacturing, clinical development, and commercial distribution are controlled within single entities. For companies that remain dependent on external isotope suppliers or contract manufacturers, the implication is that supply security is becoming a competitive differentiator.
Telix’s revenue trajectory provides context for the acquisition’s scale. The company reported A$783.2 million in 2024 revenue — above its own guidance range — and A$49.9 million in profit after tax, driven primarily by sales of its prostate cancer imaging product Illuccix (kit for the preparation of gallium-68 gozetotide), and later reported unaudited fiscal 2025 revenue of approximately US$804 million (A$1.2 billion), in line with its upgraded guidance. The ITM acquisition, at $1.65 billion upfront including $302 million in assumed net debt, represents a significant balance-sheet commitment relative to that revenue base.
The principal friction is execution complexity, not strategic logic. Telix is integrating a German isotope manufacturer — operating under European regulatory frameworks — into a network built primarily around U.S. and Australian assets. The transaction remains subject to Telix shareholder approval, regulatory approvals and other customary closing conditions, and is expected to close by the end of fiscal 2026, according to Telix; the Curium-Lantheus deal similarly remains subject to Lantheus shareholder and regulatory approval, with closing expected in the first half of 2027. A contract announced is not a contract executed; the operational reality of combining isotope production, radiopharmacy distribution, and a late-stage pipeline across multiple jurisdictions will test integration capacity that Telix has been building but has not yet demonstrated at this scale.
Christian Behrenbruch, Telix’s managing director and group chief executive officer, said: “This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures.”
On the payer side, the commercial implications of the ITM acquisition depend heavily on whether ITM-11 reaches approval and how it is positioned relative to existing neuroendocrine tumour therapies. No Medicare, commercial coverage, or national procurement decision related to ITM-11 has been disclosed; the candidate has not received FDA approval, and its NDA is awaiting resubmission after the August 2026 CRL.
What to Watch
- Telix shareholder approval and regulatory clearance of the Telix-ITM transaction, including any conditions imposed by competition or foreign-investment authorities
- The timing of ITM’s NDA resubmission for ITM-11 following the FDA’s CMC- and facility-related CRL, and the COMPOSE interim analysis expected in the first half of 2027
- Whether the Curium-Lantheus deal closes on its first-half 2027 target, and how the combined entity’s manufacturing scale affects Telix’s competitive positioning in isotope supply
THE HEALTHSIGNALS BRIEF
Track the ANVISA and COFEPRIS filings we flag here — every two weeks, in one PDF.
You're in. The next Brief lands in your inbox.
The deeper structural point is that the $700 million contingent tranche reframes what this deal is. Telix is not simply buying a supplier — it is underwriting a regulatory and commercial outcome. If ITM-11 stalls in regulatory review, the supply-chain rationale remains intact but the transaction’s total cost drops materially; if ITM-11 succeeds, the pipeline premium was cheap. That optionality is the deal’s most distinctive feature, and it is one that the Curium-Lantheus structure, built around established commercial franchises, does not replicate.
Telix-ITM Deal Structure
Upfront Consideration
$1.65B
including $1.25B in Telix shares at $11.841/share
Total Deal Value
up to $2.35B
including contingent consideration
Net Debt Assumed
$302M
included in upfront consideration
Contingent Consideration
up to $700M
regulatory approvals and sales milestones
Source: Telix Pharmaceuticals, as of 2026-09-21
Why this is relevant
Patients
Telix’s acquisition of ITM Isotope Technologies Munich adds ITM-11, a late-stage neuroendocrine tumour candidate, to its pipeline alongside an expanded isotope manufacturing network; broader patient access to targeted radiotherapies may follow if ITM-11 clears FDA review, which requires resolving the manufacturing- and facility-related issues cited in the August 2026 CRL.
Industry
Two transactions totalling up to $10.35 billion — Telix-ITM and Curium-Lantheus — announced within weeks of each other suggest the sector is consolidating around vertically integrated operators controlling isotope production, manufacturing, and clinical pipelines; companies reliant on third-party isotope supply appear increasingly exposed to a structural competitive disadvantage.
Payers
No Medicare, commercial coverage, or national procurement decision related to ITM-11 has been disclosed, as the candidate has not received FDA approval; payer implications will depend on the indication, pricing, and comparator landscape at the time of any future approval.
Litigation
The Telix-ITM transaction is subject to Telix shareholder approval and regulatory approvals, and no legal disputes have been disclosed in the available record; the Curium-Lantheus deal similarly remains pending Lantheus shareholder and regulatory approval, with closing targeted for the first half of 2027.
Sources: Telix Pharmaceuticals (21 September 2026); ITM (10 August 2026); Curium (3 August 2026); Lantheus Q1 2026 results; Telix FY2024 results; Telix FY2025 results; Fierce Pharma (September 2024).
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.
Your subscription could not be validated.
You have successfully subscribed.
